In a pilot RCT of 30 stage IV cancer patients on opioids, medical cannabis was well-tolerated and a higher proportion of early cannabis users achieved reduced opioid use and improved pain control compared to standard care.
Oncologists, palliative care providers, pain medicine specialists, and cancer patients on opioids.
Average daily cannabis doses: 34 mg THC + 17 mg CBD at 3 months
What the researchers found
High enrollment interest (36% of eligible patients enrolled). Average daily doses at 3 months were 34 mg THC and 17 mg CBD. A higher proportion of early cannabis users achieved opioid reduction and improved pain control. No serious safety issues. High patient satisfaction.
Why it matters
This study demonstrates that conducting randomized cannabis trials through state programs is feasible, a critical step toward building the rigorous evidence base needed for clinical guidelines.
The numbers in context
Enrolled: 30. Randomized 1:1. Enrollment rate: 36% of eligible. Mean daily THC: 34 mg. Mean daily CBD: 17 mg. Follow-up: 3 months. No serious adverse events.
How the study worked
Pilot RCT randomizing 30 stage IV cancer patients requiring opioids to early cannabis (n=15, immediate medical cannabis via state program) vs. delayed start cannabis (n=15, standard care for 3 months). Licensed pharmacists at dispensaries guided dosing.
What this study cannot tell us
Very small sample (n=30). Pilot design not powered for efficacy. Short 3-month follow-up. Open-label design. Single-site. Dosing varied based on dispensary pharmacist recommendations.
How to read the evidence
Randomized design is a strength, but pilot sample size and open-label design limit conclusions.
When this study was published
Published in 2021.
The bigger picture
The feasibility of conducting RCTs through state cannabis programs opens a pathway for larger, more definitive trials that have been difficult to conduct under federal restrictions.
Questions still open
- What THC-to-CBD ratio is optimal for cancer pain? Can medical cannabis meaningfully reduce opioid doses in a larger trial? How do dispensary pharmacist recommendations compare to physician dosing?
Common questions
Can medical cannabis help cancer patients reduce opioid use?
How much cannabis did cancer patients use?
Read the original research
A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(12), 7471-7478
Citation
Zylla, Dylan M; Eklund, Justin; Gilmore, Grace; Gavenda, Alissa; Guggisberg, Jordan; VazquezBenitez, Gabriela; Pawloski, Pamala A; Arneson, Tom; Richter, Sara; Birnbaum, Angela K; Dahmer, Stephen; Tracy, Matthew; Dudek, Arkadiusz. (2021). A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(12), 7471-7478. https://doi.org/10.1007/s00520-021-06301-x
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk